Cargando…

Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer

Osteoprotegerin (OPG) is a robust antiresorptive molecule that acts as a decoy receptor for the receptor activator of nuclear factor κB ligand (RANKL), the mediator of osteoclastogenesis. This study was designed to explore the possible role of serum OPG and RANKL in detecting bone metastasis in brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elfar, Gamal A., Ebrahim, Mohamed A., Elsherbiny, Nehal M., Eissa, Laila A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841017/ https://www.ncbi.nlm.nih.gov/pubmed/27983911 http://dx.doi.org/10.3727/096504016X14768398678750

Ejemplares similares

Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
por: Park, Hye-Rim, et al.
Publicado: (2003)

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
por: Trouvin, Anne-Priscille, et al.
Publicado: (2010)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

Osteoprotegerin/receptor activator of nuclear factor-κB ligand are involved in periodontitis-promoted vascular calcification
por: Jiao, Mengyu, et al.
Publicado: (2022)

Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease
por: Ugay, Ludmila, et al.
Publicado: (2016)

Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts
por: Sumida, Ryuta, et al.
Publicado: (2019)

Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients
por: Carmona-Fernandes, Diana, et al.
Publicado: (2011)

Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteoblasts in vivo and in vitro
por: LI, JINGWU, et al.
Publicado: (2016)

The Effects of Receptor Activator of NF-κB Ligand-Binding Peptides on Bone Resorption and Bone Formation
por: Rashed, Fatma, et al.
Publicado: (2021)

The Role of Osteoprotegerin and Its Ligands in Vascular Function
por: Rochette, Luc, et al.
Publicado: (2019)

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
por: Lambrinoudaki, Irene, et al.
Publicado: (2013)

Increase in receptor activator of nuclear factor κB ligand/osteoprotegerin ratio in peri-implant gingiva exposed to Porphyromonas gingivalis lipopolysaccharide
por: Shuto, Takahiro, et al.
Publicado: (2016)

Imbalance of osteoprotegerin/receptor activator of nuclear factor-κB ligand and oxidative stress in patients with obstructive sleep apnea-hypopnea syndrome
por: Ma, Xiao-Rong, et al.
Publicado: (2019)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
por: Burgess, Teresa L., et al.
Publicado: (1999)

Phenethyl isothiocyanate Triggers Apoptosis, Combats Oxidative Stress and Inhibits Growth of Ehrlich Ascites Carcinoma Mouse Model
por: Eisa, Nada H., et al.
Publicado: (2018)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid
por: Sarlati, Fatemeh, et al.
Publicado: (2012)

IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
por: Guerra-Menéndez, Lucia, et al.
Publicado: (2013)

The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis
por: Zang, Leyuan, et al.
Publicado: (2015)

RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)

Osteoprotegerin in Bone Metastases: Mathematical Solution to the Puzzle
por: Ryser, Marc D., et al.
Publicado: (2012)

Osteoprotegerin in breast cancer: beyond bone remodeling
por: Weichhaus, Michael, et al.
Publicado: (2015)

Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy
por: Styczynska, Hanna, et al.
Publicado: (2009)

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
por: Cawley, Keisha M., et al.
Publicado: (2020)

Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis
por: Giaginis, Constantinos, et al.
Publicado: (2012)

Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in human osteoblasts
por: ZHANG, YUANYU, et al.
Publicado: (2015)

Amelioration of ethanol-induced gastric ulcer in rats by quercetin: implication of Nrf2/HO1 and HMGB1/TLR4/NF-κB pathways
por: Shams, Shams Gamal Eldin, et al.
Publicado: (2022)

Osteoprotegerin in Cardiometabolic Disorders
por: Pérez de Ciriza, C., et al.
Publicado: (2015)

Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study
por: Lien, Gunhild, et al.
Publicado: (2010)

Bone Alterations in Inflammatory Bowel Diseases: Role of Osteoprotegerin
por: Priadko, Kateryna, et al.
Publicado: (2022)

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
por: Tabari, Zahra Alizadeh, et al.
Publicado: (2013)

Resveratrol-mediated SIRT-1 Interactions with p300 Modulate Receptor Activator of NF-κB Ligand (RANKL) Activation of NF-κB Signaling and Inhibit Osteoclastogenesis in Bone-derived Cells
por: Shakibaei, Mehdi, et al.
Publicado: (2011)

Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis
por: Weichhaus, Michael, et al.
Publicado: (2014)

Effect of Breastfeeding on Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappa B Ligand in Full Term Neonates
por: Rafeey, Mandana, et al.
Publicado: (2013)

In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications
por: Jayash, Soher Nagi, et al.
Publicado: (2016)

The Effect of Orthognathic Surgery on Osteoprotegerin as Immunological Caliper of Bone Healing
por: Soliman, Sara, et al.
Publicado: (2016)

The roles of osteoprotegerin in cancer, far beyond a bone player
por: Wang, Yufei, et al.
Publicado: (2022)

Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin
por: Wu, Colleen, et al.
Publicado: (2015)

Receptor activator of NF-κB ligand induces cell adhesion and integrin α2 expression via NF-κB in head and neck cancers
por: Yamada, Tamaki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j7rbqvn8n3h0ssb87trt3qs8oq